01 — At a Glance
The Formulation Juggernaut Nobody Invited to the Party
- 52-Week High / Low₹1,279 / ₹994
- Q3 Revenue₹8,646 Cr
- Q3 PAT₹910 Cr
- Q3 EPS₹15.67
- Annualised EPS (Q3×4)₹62.68
- Book Value₹603
- Price to Book2.04x
- Dividend Yield0.32%
- Debt / Equity0.22x
- ROCE14.2%
The Auditor Says: Aurobindo closed Q3 FY26 with ₹8,646 crore revenue (+8.4% YoY), ₹910 crore PAT, 20.5% EBITDA margin, and dropped a Pomalidomide generic launch in the US market on the same day the results came out. P/E ratio is 20.3x against sector median of 27.6x. Not overvalued by pharma standards. Not cheap either. Fair game. Europe revenue grew 27% YoY — that’s the story hiding in plain sight.
02 — Introduction
The Second-Largest Pharma Company That Never Wins Awards
Here’s a fun fact: Aurobindo Pharma is India’s second-largest listed pharmaceutical company by revenue. They make generics. Active pharmaceutical ingredients (APIs). Injectable formulations. And they’re one of the few Indian pharma companies that can build a penicillin plant from scratch and actually make it work profitably.
But they’re not the sexy stock in your portfolio. No COVID tailwinds. No biotech halo. No “India’s answer to Moderna” nonsense. Just 853 ANDA filings with the US FDA, presence in 150+ countries, manufacturing footprints in India, Portugal, Brazil, and the US, and a business model that quietly prints cash every quarter.
Q3 FY26 is when things get interesting. Europe is growing 27% YoY. APIs — the boring ingredient business — is scaling profitably. And the government just protected Indian antibiotic makers with a Minimum Import Price (MIP) policy that makes Aurobindo’s Pen-G strategy print money starting Q4 FY26. The concall transcripts from February 2026 tell a story of a company that’s about to enter a different growth phase. Let’s parse what’s actually happening.
Concall Note (Feb 2026): “Low double digit growth in Europe is well ahead of the market growth rate.” Management expects Europe to cross €1 billion in annual run-rate by the end of FY26. That’s a goal. That’s execution. That’s the trajectory of a ₹70k+ crore market-cap company pivoting regionally.
03 — Business Model: Who Are They?
Generics. Injectables. Antibiotics. And Pills That Save Lives.
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
